Lung resection, a critical treatment for various thoracic diseases, including lung cancer, often necessitates prolonged hospitalization due to rare but severe postoperative complications such as chyle leaks, with an occurrence of 0.25%-3%, prolonging chest drainage, and delaying recovery. Therefore, effective postoperative care is essential for optimizing outcomes, reducing complications, and expediting recovery. Recent studies have highlighted the significant potential of medium-chain triglyceride (MCT) diets, owing to their unique absorption pathway and metabolic properties. MCT contains mainly medium-chain fatty acids (MCFA), which is absorbed in the intestine and transported to the liver via the portal system instead of the lymphatic system. This helps to bypass the lymphatic system, thereby reducing the volume of lymph. MCFAs also provide better energy utilization in stressed condition since it does not require carnitine shuttle upon metabolism, which is beneficial to post-operation recovery. Several studies have demonstrated the benefits of MCT diets in managing chyle leaks and supporting gastrointestinal recovery, particularly in conditions that strain the lymphatic system. For instance, short-term MCT-enriched diets have been associated with improved post-operation recovery of gastrointestinal, hepatic and renal functions, reduced total chest drainage volumes, and shorter hospital stay when compared to regular diet groups. Patients with post-operative chyle leak following thoracic surgery are often given an MCT diet to reduce chest drain volume and hence shorten hospital stay. Based on the successful use of MCT diet on patients with chyle leak after lobectomy, it is hypothesized that patients with chylothorax provided with post-operative MCT diet can also shorten hospital stay by decreasing chest drainage. Therefore, a prospective and randomized trial is designed to investigate how post-operative MCT diet in lung resection patients without chylothorax may affect hospital stay and post-operative recovery.
This study is a single-center, prospective, randomized trial designed to investigate how a post-operative diet enriched with MCT affects recovery in patients undergoing video-assisted thoracic surgery (VATS). Medical students from the Chinese University of Hong Kong, under the supervision of the principal investigator, will conduct the study, including obtaining consent and collecting data. Experienced surgeons at the Prince of Wales Hospital will perform the VATS procedures. 2.2 Hypotheses 1. MCT diet can speed up post-operative recovery and shorten hospital length of stay. 2. MCT diet poses no adverse effects in post-operative recovery for patients without chyle leak following lung surgery. 3. The use of MCT diet after discharge for 2 weeks can enhance patient recovery and possibly reduce readmissions or complications.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
210
MCT diet for patients following lung resection
Prince of Wales Hospital
Shatin, Hong Kong
hospital length of stay (LOS)
hospital length of stay (LOS), which is hypothesized to be reduced following the administration of an MCT diet. Currently, patients undergoing lobectomy using VATS have a median LOS of approximately 3-4 days. The study aims to investigate whether MCT diet interventions can reduce this to 2 days, representing a 30% reduction in hospital stay.
Time frame: From the end of the lung resection procedure until the time of patient discharge, assessed up to 7 days post-surgery
Total Chest Drain Output (mL)
Chest drain output indirectly reflects recovery status. The total chest drain output will be measured using the Medela digital chest drainage system, which is routinely used for patients undergoing lobectomy. Compared to manual drainage system, this system allows more precise monitoring of fluid output. This information will help evaluate the overall impact of the MCT diet on postoperative recovery, particularly in reducing fluid drainage.
Time frame: From the end of the lung resection procedure until the time of chest drain removal assessed up to 7 days post-surgery
Patient Satisfaction and Tolerability
Patient-reported outcomes will be assessed using a quality of life (QoL) questionnaire, which is an established tool for evaluating recovery after surgery. The questionnaire will include: * Patient satisfaction with their recovery process * Tolerability of the MCT diet * Any challenges experienced during the diet, including adherence and acceptability
Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge
Number of Participants with Symptoms Associated with MCT Diet
Patients will be monitored for any gastrointestinal discomfort associated with the MCT diet, including: * Diarrhea * Constipation * Bloating * Increased flatus Reports of these symptoms will be collected during the hospital stay and follow-up visits to assess the safety and tolerability of the MCT diet.
Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge
Number of patients with Infection symptoms
· Observing for symptoms such as fever or shortness of breath (SOB), which will be incorporated into the QoL questionnaire
Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge
Number of patients with infection risk
Regular checks for pleural-based complications, such as effusion, through chest X-rays (performed before discharge and during follow-ups)
Time frame: Upon discharge (assessed up to 7 days post-surgery), 2 weeks post discharge, 3 months post discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.